Zelira Therapeutics brings deep
pharmaceutical expertise to the
development and commercialisation of our
proprietary cannabinoid-based medicines.
Zelira Therapeutics…with our focus on specific
conditions, we are ‘reimagining healthcare’
for millions of people underserved by
current treatments.
We are committed to building patient and
doctor confidence in our medicines with
an ethical, evidence-based approach,
applying world-class science and
conducting clinical trials.
Zelira Therapeutics - Global Leader in cannabinoid-based medicine
Zelira Therapeutics Ltd is a leading global cannabinoid-based biopharmaceutical company with access to the world’s largest and fastest growing markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets. The Company is focused on developing branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.

Doctors + Specialists
Supporting healthcare professionals and patients with cannabinoid-based medicines

Pharmacists
Supporting healthcare professionals and patients with cannabinoid-based medicines
Recent Video and Audio from Zelira Therapeutics
May 12, 2022
https://www.youtube.com/watch?v=mvlllwtZdYg
Zelira Therapeutics Investor Presentation
Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Dr Oludare Odumosu deliver a slide presentation and answer investor questions as part of a business update.
February 27, 2022
https://www.youtube.com/watch?v=A58M-Ylg0hc
Channel 7 News Perth
Zelira product helping young patient with autism spectrum disorder
January 13, 2022
https://bcove.video/3rfBWM7
Zelira AGM Presentation January 2022
CEO Oludare Odumosu and Chairman Osagie Imasogie presentation at the Zelira AGM 2022
September 1, 2021
https://zeliratx.com/presentations/Proactiveinvestors_AU_-_Zelira_Therapeutics_commercialisation_program_to_see_launch_of_suite_of_new_cannabinoid-based_prod.pdf
Zelira Therapeutics’ commercialisation program
Zelira to launch a suite of new cannabinoid-based products in FY22 – Proactive
August 25, 2021
https://www.youtube.com/watch?v=muhK--qz0hY
Channel 9 News Perth
Zelira Therapeutics and Curtin University partner on research of proprietary technology that demonstrates significant uptake of CBD into the brain
June 29, 2021
https://zeliratx.com/presentations/Zelira_Therapeutics-Cantor_Presentation-June_29_2021.pdf
Presentation at Cantor Fitzgerald International Cannabis Forum
Zelira Therapeutics Investor Slide Deck